AZ201801 is a multicenter study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) and evaporative Dry Eye Disease (DED)
AZ201801 is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study carried out in 2 sequentially overlapping cohorts evaluating the safety, efficacy and tolerability of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) and evaporative Dry Eye Disease (DED)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
321
AZR-MD-001 is an ophthalmic ointment
AZR-MD-001 is an ophthalmic ointment
AZR-MD-001 is an ophthalmic ointment
Meibomian Glands Yielding Liquid Secretion (MGYLS)
Change from Baseline in MGYLS. The MGYLS can range from 0 (abnormal) to 15 (normal)
Time frame: Value at month 3 minus value at baseline
Ocular Surface Disease Index (OSDI) Total Score
Change from Baseline in OSDI Total Score. The OSDI Total Score can range from 100 (highly abnormal) to 0 (Normal)
Time frame: Value at month 3 minus value at baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
AZR-MD-001 is a vehicle ophthalmic ointment
Vision Eye Institute
Chatswood, New South Wales, Australia
Eye Associates
Sydney, New South Wales, Australia
Sydney Eye Hospital
Sydney, New South Wales, Australia
School of Optometry and Vision Science, University of New South Wales
Sydney, New South Wales, Australia
Queensland University of Technology
Brisbane, Queensland, Australia
Queensland Eye Institute
South Brisbane, Queensland, Australia
Ophthalmic Trials Australia
Teneriffe, Queensland, Australia
Eye Laser Specialists
Armadale, Victoria, Australia
Bendigo Eye Clinic
Bendigo, Victoria, Australia
Waverley Eye Clinic
Glen Waverley, Victoria, Australia
...and 20 more locations